Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 585 results for "lymphocyte count"

Lymphocyte count predicts papillary RCC patient survival

medwireNews: Lymphopenia is a significant predictor of outcome in patients undergoing surgery for papillary renal cell carcinoma (PRCC), US researchers report. The team says that the preoperative absolute lymphocyte count (ALC), a marker of ... MedWire News, 1 week ago

New cholesterol guidelines can significantly help reduce cardiovascular events

Lymphocyte count predicts papillary RCC patient survival Physical activity fails to show link with chronic musculoskeletal pain A study from UT-Southwestern researchers found that recently introduced cholesterol guidelines would significantly ...
 News-Medical.Net1 week ago Study on patients with type 2 diabetes examines fracture risk with antihypertensive treatment  News-Medical.Net1 week ago

CD4 T-Lymphocyte Percentages Corresponding to CD4 T-Lymphocyte Count Thresholds in a New Staging System for HIV Infection

JAIDS Journal of Acquired Immune Deficiency Syndromes. 66(4):e92-e94, August 1, 2014. Email to a Colleague Colleague's E-mail is Invalid Your Name: (optional) Your Email: Colleague's Email: Separate multiple e-mails with a (;). ...
 JAIDS2 months ago

Roche receives EC approval for chronic lymphocytic leukemia drug

Roche has received approval from the European Commission, or EC, for Gazyvaro in combination with chlorambucil chemotherapy for the treatment of people with previously untreated chronic lymphocytic leukemia who have comorbidities making them ...
 Individual.com3 weeks ago EU approves Roche's Gazyvaro to treat patients with most common type of leukaemia  PharmaBiz1 month ago Roche's Gazyvaro approved in Europe for patients with the most common type of leukemia  Noodls1 month ago Roche???s Gazyvaro Approved In Europe For Patients With The Most Common Type Of Leukemia  BioSpace1 month ago
[x]  

Amgen: Grappling With The Reality Of Patent Expiries

Summary Amgen has been recently awarded the breakthrough status for its new drug to treat adults with acute lymphoblastic leukemia. The prevalence rate is quite high, with limited treatment options available. If authorized, Amgen can exploit the ...
 Seeking Alpha1 month ago
Reuters

Record-Breaking Year for The Leukemia & Lymphoma Society's Man & Woman of the Year campaign

-COMMUNITY LEADERS RAISED $30.5 MILLION TO HELP FIND CANCER CURES- PR Newswire WHITE PLAINS, N.Y., July 17, 2014 WHITE PLAINS, N.Y., July 17, 2014 /PRNewswire/ -- A Chicago man and Los Angeles woman raised $386,284 and $343,962, ...
 Reuters1 month ago
[x]  

New Summary: Chronic lymphocytic leukemia. [CancerControl Alberta]

Guideline Title Chronic lymphocytic leukemia. Bibliographic Source(s) ...
 National Guideline Clearinghouse1 month ago Navidea Biopharmaceuticals' (NAVB) CEO Michael Goldberg on Investor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers (Transcript)  Seeking Alpha1 month ago Updated Summary: Lymphoma. [CancerControl Alberta]  National Guideline Clearinghouse2 months ago Updated Summary: Preoperative and pretreatment investigations for malignant melanoma. [CancerControl Alberta]  National Guideline Clearinghouse1 month ago

Anakinra for Secondary Hemophagocytic Lymphohistiocytosis

Surender Rajasekaran, MD, MPH, Katherine Kruse, MD, Karen Kovey, PharmD, Alan T. Davis, PhD, Nabil E. Hassan, MD, Akunne N. Ndika, MBBS, MPH, Sandra Zuiderveen, BSN, RN, James Birmingham, MD Disclosures Pediatr Crit Care ...
 General Medicine eJournal2 months ago
Emirates Week

Clinical Study in the Journal of Clinical Oncology Reports Patients with Diffuse Large B-Cell Lymphoma Receiving Oral REVLIMID with Standard R-CHOP Achieved 98% Overall Response Rate and 80% Complete Response Rate

/Business Wire SUMMIT, N.J. Thursday, August 21st 2014 Celgene Corporation (NASDAQ:CELG) today announced that results of a study evaluating the combination of REVLIMID® (lenalidomide) with rituximab, cyclophosphamide, doxorubicin ...
 Emirates Week1 week ago CELGENE : Clinical Study in the Journal of Clinical Oncology Reports Patients with Diffuse Large B-Cell Lymphoma Receiving Oral REVLIMID with Standard R-CHOP Achieved 98% Overall Response Rate and 80% Complete Response Rate  4 Traders1 week ago Initial Treatment with VELCADE® Improves Outcomes of Patients with Mantle Cell Lymphoma  CancerConnect.com1 month ago Galena Biopharma Reports Second Quarter 2014 Results  BusinessWeek2 weeks ago
[x]  

U.S. FDA Grants Regular (Full) Approval for IMBRUVICA® for Two Indications

Previously Treated Chronic Lymphocytic Leukemia (CLL) Based on Statistically Significant Progression-Free and Overall Survival Benefits SUNNYVALE, Calif., July 28, 2014 /PRNewswire/ — Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the ...
 Red Orbit1 month ago PHARMACYCLICS : U.S. FDA Grants Regular (Full) Approval for IMBRUVICA® for Two Indications  4 Traders1 month ago Pharmacyclics: U.S. FDA Grants Regular Approval for Imbruvica [Manufacturing Close - Up]  Pharmacy Choice4 weeks ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less